RecruitingPhase 1Phase 2NCT07794475

Effect of Trimetazidine on Endothelin-1 and Clinical Outcomes of Patients With Diabetic Peripheral Neuropathy

Sponsor

Sara Refaat Azab Metry

Enrollment

60 participants

Start Date

Aug 1, 2026

Study Type

INTERVENTIONAL

Conditions

Diabetic Peripheral Neuropathic Pain (DPN)

Summary

The goal of this clinical trial is to investigate if trimetazidine can improve clinical outcomes of patients with diabetic peripheral neuropathy. The main questions it aims to answer are: Does trimetazidine improve the symptoms of diabetic peripheral neuropathy? Does trimetazidine affect endothelin-1 levels? Participants in the interventional arm will receive trimetazidine tablets 35 mg twice daily for three months.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Trimetazidine Dihydrochloride Tablets for people with diabetic peripheral neuropathic pain (dpn). The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.